The hypothesis that L-DOPA therapy in Parkinson's disease may augment neuronal damage and thus accelerate the progression of the disease remains controversial. In this study, we demonstrate that L-DOPA induces death of catecholaminergic cells in vitro via an active program of apoptosis. Treatment of PC12 cells with clinically applicable concentrations of L-DOPA (25-100 ,uM) induced cell death via a mechanism which exhibited morphological and biochemical characteristics of apoptosis, including chromatin condensation, membrane blebbing, and internucleosomal DNA fragmentation. L-DOPA-induced apoptosis was cell and drugtype specific. Toxicity is an intrinsic property of the drug molecule since it was not suppressed by inhibiting conversion of L-DOPA to dopamine. However, L-DOPA toxicity was inhibited by antioxidants, suggesting that activation of apoptosis is mediated by oxygen radicals. Our finding that L-DOPA-induced cell death in vitro occurs via apoptosis explains the lack of evidence supporting its toxicity in vivo, since apoptotic neurons are rapidly phagocytosed in vivo without causing damage to surrounding tissue. Furthermore, since apoptosis is an active cellular program which can be modulated, we suggest clinical approaches for decreasing L-DOPA toxicity, thus preventing acceleration of neuronal damage in Parkinson's disease. (J. Clin. Invest. 1995Invest. . 95:2458Invest. -2464
Introduction
Parkinson's disease is characterized by selective degeneration of dopaminergic neurons in the substantia nigra. The etiology of this disease remains unknown, but one hypothesis is that endogenous or exogenous neurotoxins may be responsible for the destruction of nigrostriatal neurons. Current clinical therapies for Parkinson's disease are limited and the few treatments that are available alleviate the neurological symptoms of the disease rather than the primary event of cell death. L-3,4-dihy-cursor to dopamine, is the most effective and frequently prescribed therapy for controlling the symptoms of Parkinson's disease (1) . It remains the drug of choice in the treatment of this disease despite the fact that there are limiting adverse side effects associated with chronic L-DOPA treatment. The major side effects are central and include the appearance of involuntary movements (dyskinesia), fluctuations in motor performance ("on-off " phenomenon), and psychiatric complications (1) (2) (3) (4) . In addition, the effects of L-DOPA therapy on the progression of Parkinson's disease are unknown and conflicting reports have suggested that L-DOPA may or may not accelerate deterioration of the patients (5) (6) (7) (8) (9) (10) . L-DOPA produces initial improvements in dopaminergic function, but therapy is only successful for a limited period of time after which patients become unresponsive and neurological disability reappears and worsens (2, 3) . Despite this eventual decline in "effectiveness," L-DOPA remains the most successful drug used to treat Parkinson's disease and is often administered successfully for many years before treatment becomes unsatisfactory.
Several recent studies have demonstrated that L-DOPA is toxic to some neuronal cells in vitro (11) (12) (13) (14) (15) . It has been suggested from these studies that long-term administration of L-DOPA to patients with Parkinson's disease may exacerbate neuronal damage and thus accelerate the progression of the disease. However, this hypothesis has remained unsubstantiated due to a lack of evidence supporting L-DOPA toxicity in vivo. It has been shown in both rats ( 16) and mice ( 17) that long-term administration of L-DOPA does not cause detectable damage to nigrostriatal dopaminergic neurons. Furthermore, no evidence of damage to nigral neurons was found in a normal individual consuming large amounts of L-DOPA over a prolonged period ( 18) . However, recent in vivo studies, involving chronic administration of L-DOPA to animals in which dopaminergic neurons have been damaged previously by exposure to 6-hydroxydopamine, have provided some evidence that L-DOPA toxicity may also occur in vivo (19, 20) .
Although toxicity of L-DOPA towards catecholaminergic neurons has been demonstrated in cell cultures (11) (12) (13) (14) (15) , the mechanism by which L-DOPA, especially at clinically relevant concentrations, induces cell death has not been investigated. Cell death is proposed to occur by two distinct mechanisms, necrosis and apoptosis. Necrosis is a passive, uncontrolled form of cell death, typically observed in response to an acute toxic insult. Necrotic cells lose control of cellular homeostasis, swell, and undergo cell lysis, thus causing inflammation and damage to surrounding tissue. In contrast, apoptosis is an active form of cell death involving the participation of the cell in an internal program of self-destruction. This physiological "cellular suicide" plays an important role in embryonic development, particularly development of the nervous system (21, 22) . Apoptosis can be recognized by distinct morphological and biochemical features (23, 24) . Apoptotic cells shrink in size, undergo membrane blebbing, and exhibit highly condensed chromatin. The biochemical hallmark of apoptosis is cleavage of DNA into regular sized fragments, typically large fragments of 50 kb and often into multiples of 180 bp internucleosomal fragments (25) (26) (27) . These latter fragments give a characteristic "ladder" pattern when separated by agarose gel electrophoresis.
An important feature of apoptotic cell death in vivo is that dying cells maintain their membrane integrity and are rapidly phagocytosed by neighboring cells or patrolling macrophages, leaving no trace of their existence and causing no damage to surrounding tissue (23, 28) . We 
Results
Characterization of L-DOPA-induced toxicity. Initial experiments were carried out to determine whether catecholaminergic PC12 cells were susceptible to the toxic effects of L-DOPA.
Treatment of PC12 cells with 200 ,M L-DOPA, a concentration which has been shown in previous studies to be toxic to other catecholaminergic cells (11) (12) (13) , resulted in a decrease in viable cell number after 24 h (data not shown). This observation confirmed that PC12 cells were sensitive to L-DOPA toxicity and therefore could be used to examine the mechanism by which L-DOPA induces cell death.
To investigate the morphology of L-DOPA-induced cell death, a lower and more clinically applicable concentration was used. PC12 cells were treated with 50 MM L-DOPA for 24 h. via a mechanism which possessed characteristic morphological features of apoptotic cell death, including highly condensed chromatin and extensive membrane blebbing (Fig. 1 B) . Stain- ing of the cells with trypan blue indicated that, at this concentration, L-DOPA did not induce necrotic cell death. The only cells which stained with trypan blue were small, shrunken cells which had undergone "secondary necrosis." This is a term used to describe the fate of an apoptotic cell in vitro. Although an apoptotic cell maintains its membrane integrity initially, if it is not phagocytosed it eventually starts to disintegrate and becomes permeable to dyes such as trypan blue. A biochemical hallmark of apoptosis observed in many cells is the characteristic cleavage of DNA at internucleosomal sites to produce a DNA ladder (25) . The integrity of DNA from PC12 cells induced to die by treatment with L-DOPA was examined by agarose gel electrophoresis (Fig. 1 C) . Cells detaching from the viable monolayer between 16 and 24 h after treatment with 50 MM L-DOPA were collected and pooled. Analysis of DNA extracted from these cells revealed the classical fragmentation pattern typical of apoptosis ( Fig. 1 C, lanes 3, 4, 6 , and 7). DNA fragmentation was not observed in untreated control cells ( Fig. 1 C, lanes 1 and 2) (Fig. 2 B) . At higher concentrations of L-DOPA (above 200 MM), necrosis was the predominant form of cell death (not shown).
Specificity of L-DOPA-induced apoptosis. To investigate whether the induction of apoptosis by L-DOPA was specific to catecholaminergic cells, or a general phenomenon observed in all cell types, the effect of L-DOPA on noncatecholaminergic cells was examined. The noncatecholaminergic cells chosen for this investigation were FaO rat hepatoma cells and rat-i fibroblasts. Fig. 3 A shows (Fig. 3 B) . No apoptotic cell death was observed after treatment of PC12 cells with 50 MM phenylalanine (an aromatic amino acid), arginine (a basic amino acid), or serine (a neutral amino acid).
Investigation into the mechanism of L-DOPA-induced apoptosis. It has been demonstrated previously that dopamine is toxic to dopaminergic cells in vitro ( 14, 34) . Thus, we consid- tigated by preventing the conversion of L-DOPA to dopamine using carbidopa, an inhibitor of the decarboxylase which catalyzes this conversion. The amount of apoptosis observed in PC12 cell cultures treated for 24 h with 50 1M L-DOPA + 25 jiM carbidopa was not significantly different from that observed in cultures treated with 50 [M L-DOPA alone (Fig. 4 A) . PC12 cells were also treated with 50 [M dopamine to determine whether dopamine itself induced apoptosis in these cells. Although an induction of apoptosis was observed in cultures treated with 50 pM dopamine for 24 h, the amount of apoptosis was significantly less than that induced after treatment with 50 jiM L-DOPA for 24 h (Fig. 4 A) .
Reactive oxygen species such as hydrogen peroxide and associated oxy radicals can be generated during the autoxidation of L-DOPA. To investigate whether the induction of apoptosis by L-DOPA was mediated by generation of reactive oxygen species, the ability of antioxidants to inhibit L-DOPA-induced apoptosis was examined. PC12 cells were treated with 50 MM L-DOPA alone or in the presence of one of the following antioxidants: 100 1M vitamin E, 1 mM glutathione, or 100 ,LM ascorbic acid. Fig. 4 B shows the amount of apoptosis induced 24 h after addition of the drugs. Induction of apoptosis by L-DOPA was completely inhibited by addition of glutathione or ascorbic acid. Induction of apoptosis by L-DOPA was also inhibited, although to a lesser extent, by vitamin E.
Olney and colleagues (35) have reported that high concentrations of L-DOPA ( 1-2 mM) exhibit weak excitotoxic properties in the chick embryo retina. L-DOPA excitotoxicity was shown to be blocked by CNQX, an antagonist at non-NMDA subtypes of excitatory amino acid receptors (35) . To investigate whether the induction of apoptosis by L-DOPA was (5) (6) (7) (8) (9) (10) . In this study, we have demonstrated that L-DOPA is toxic to catecholaminergic PC12 cells in vitro and that at clinically relevant concentrations this toxicity is mediated via an apoptotic mechanism rather than via a necrotic process. The concentration of L-DOPA reported in human plasma after administration of an average dose of 1,000 mg of L-DOPA (e.g., 1,000 mg/70 kg person = 14.3 mg/kg) is 1.7 ,ig/ml (8.6 x 10-6 M) (15) . However, there is a lack of information available regarding the tissue levels of L-DOPA in parkinsonian patients treated with this drug. In animals treated with L-DOPA (100 mg/kg), striatal concentrations of the drug reached 15-30 x 10-6 M (36). Although the average dose of L-DOPA administered to patients is severalfold lower than the dose used in the above experiment in animals, the concentrations of L-DOPA expected in the striatum of patients with Parkinson's disease are close to the range of concentrations used in our study. Therefore, although it is difficult to extrapolate the concentrations of L-DOPA used in our study to a clinical situation, where large swings in plasma levels are produced by standard L-DOPA treatments, we observe induction of apoptosis with concentrations of L-DOPA which could quite possibly be reached in patients. Necrotic cell death is observed with higher concentrations of drug, as has been described in previous studies of L-DOPA toxicity (11) (12) (13) (14) (15) . Although the toxic effects of L-DOPA reported in this study are of a far lesser magnitude than the neurotoxic effects of a dopaminergic toxin such as MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine), the cumulative effect of a small, but highly significant, amount of apoptosis might be predicted to be catastrophic in a nucleus containing a small number of post-mitotic cells. Our finding that L-DOPA-induced cell death occurs via an active "suicide" pathway which is controlled by the cell, rather than simply being an uncontrolled loss of cellular homeostasis, provides an explanation for conflicting observations made in recent studies of the effect of L-DOPA in vivo, and has several implications for the treatment of Parkinson's disease.
Although L-DOPA toxicity has been reported previously in catecholaminergic cells in vitro (11) (12) (13) (14) (15) , several studies have examined the effect of chronic administration of L-DOPA in vivo in normal healthy animals and found no evidence of neuronal damage, although extensive quantitation of the number of nigral cells remaining after drug treatment was not performed (16, 17) . Damage to nigrostriatal dopaminergic neurons could not be detected after chronic treatment of rats (16) that after a toxic insult, necrotic cell death will occur irrespective of other factors, whereas because apoptosis is an active cellular process, the susceptibility of a cell to undergo apoptotic cell death in response to a certain stimuli can (38) . This clinical trial, however, did not investigate the effect of tocopherol in patients being treated with L-DOPA. The patients used in the study were untreated patients with Parkinson's disease, and the end point of the trial was the onset of disability prompting the clinical decision to withdraw tocopherol treatment and to begin administering L-DOPA. Thus, the effects of coadministering antioxidants with L-DOPA on the progression of Parkinson's disease were not investigated in the DATATOP study (38) . Our data show that L-DOPA-induced apoptosis is mediated via generation of reactive oxygen species and can be completely prevented by certain antioxidants in vitro. A recent study has demonstrated that L-DOPA also increases production of hydroxyl radicals in the substantia nigra in vivo (39) . We suggest that an approach to improving L-DOPA therapy would be to elevate the depleted levels of free radical scavenging agents in the substantia nigra of parkinsonian patients perhaps by coadministration of antioxidants. This adjuvant therapy might protect dopaminergic neurons from L-DOPA-induced apoptosis.
Our finding that L-DOPA induces cell death via an apoptotic mechanism may also have implications in patients with Parkinson's disease who are being considered for transplant therapy with grafts of fetal catecholaminergic cells. During embryonic development, the nervous system is shaped into its final form by a process that involves apoptosis of over 50% of the developing neurons (21) . It is possible that during this developmental stage fetal neurons are primed to undergo apoptosis and are therefore more susceptible to activation of an apoptotic pathway by L-DOPA. It has been demonstrated that chronic administration of L-DOPA impairs both the development of grafts of fetal nigral neurons in 6OHDA lesioned animals (15) , and subsequent recovery of rotational behavior after grafting (40) . We suggest that fetal neurons will also be susceptible to the toxic effects of L-DOPA and may have an increased propensity to undergo apoptosis. This hypothesis supports the idea that withdrawal of post-implantation L-DOPA therapy in patients with Parkinson's disease who have received a fetal graft may increase the success of graft survival.
We were interested to determine whether the free radical damage which leads to apoptosis of PC12 cells is generated during the conversion of L-DOPA to dopamine, or even by dopamine itself. Direct application of dopamine to PC12 cells did induce apoptosis, but to a far lesser extent than did L-DOPA. The induction of apoptosis by L-DOPA could not be inhibited by preventing the conversion of L-DOPA to dopamine using carbidopa, an inhibitor of the enzyme which catalyzes this conversion. Thus L-DOPA appears to be an intrinsically toxic molecule, and therapeutic approaches could be made which might protect against the noxious side effect of L-DOPA, but retain the beneficial property of conversion to the active metabolite, dopamine. It can be envisaged that clinically, separation of toxicity and pharmacological activity might be achieved by the development of an L-DOPA analogue which could be converted to a dopaminergic agonist with efficacy on dopamine receptors, but which failed to exhibit formation of free radicals when metabolized. A more immediate clinical objective would be coadministration of antioxidants which remove the potential toxicity of L-DOPA but retain its conversion to dopamine.
This paper presents evidence that L-DOPA, the most successful and frequently prescribed drug for alleviating the symptoms of Parkinson's disease, is toxic to catecholaminergic cells and that this toxicity is mediated by a process of apoptosis. Apoptosis is a form of cell death with active kinetics, thus the toxicity of the drug may be considerably reduced by changes in the therapeutic regimen such as giving the minimum effective dose and avoiding fluctuations in serum levels by using slow release preparations ( 1) . Since the induction of apoptosis by L-DOPA does not appear to be inextricably linked to its pharmacological activity, the toxicity may be viewed as a side effect which may be abrogated by, for example, the use of antioxidants, without loss of therapeutic benefit. Furthermore, we believe that L-DOPA-induced apoptosis of nigral neurons may underlie the decrease in efficacy observed with long-term administration of this anti-parkinsonian agent and may be responsible for accelerating the progression of neuronal degeneration in Parkinson's disease.
